DC
AZN icon

Davenport & Co’s AstraZeneca AZN Stock Holding History

Davenport & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Buy
32,897
+1,600
+5% +$301K 0.03% 328
2026
Q1 		$6.17M Buy
31,297
+6,769
+28% +$1.31M 0.03% 303
2025
Q4 		$4.51M Buy
24,528
+89
+0.4% +$15.6K 0.02% 361
2025
Q3 		$3.75M Buy
24,439
+15,530
+174% +$2.35M 0.02% 400
2025
Q2 		$1.25M Buy
8,909
+452
+5% +$63.3K 0.01% 635
2025
Q1 		$1.24M Buy
8,457
+1,448
+21% +$209K 0.01% 607
2024
Q4 		$918K Sell
7,009
-259
-4% -$36.3K 0.01% 662
2024
Q3 		$1.13M Buy
7,268
+362
+5% +$58.4K 0.01% 608
2024
Q2 		$1.08M Buy
6,906
+689
+11% +$104K 0.01% 603
2024
Q1 		$842K Sell
6,217
-63
-1% -$8.34K 0.01% 658
2023
Q4 		$846K Sell
6,280
-22
-0.3% -$2.86K 0.01% 619
2023
Q3 		$854K Sell
6,302
-426
-6% -$58.2K 0.01% 583
2023
Q2 		$963K Buy
6,728
+139
+2% +$20.5K 0.01% 568
2023
Q1 		$915K Sell
6,589
-9,365
-59% -$1.26M 0.01% 563
2022
Q4 		$2.16M Sell
15,954
-589
-4% -$73.9K 0.02% 360
2022
Q3 		$1.81M Sell
16,543
-690
-4% -$87.5K 0.02% 373
2022
Q2 		$2.28M Sell
17,233
-3,200
-16% -$420K 0.02% 348
2022
Q1 		$2.71M Buy
20,433
+3,764
+23% +$451K 0.02% 345
2021
Q4 		$1.94M Buy
16,669
+11,047
+196% +$1.3M 0.01% 411
2021
Q3 		$675K Sell
5,622
-42
-0.7% -$4.89K ﹤0.01% 640
2021
Q2 		$678K Buy
5,664
+28
+0.5% +$3.07K 0.01% 568
2021
Q1 		$560K Sell
5,636
-175
-3% -$17.6K 0.01% 516
2020
Q4 		$581K Sell
5,811
-100
-2% -$10.6K 0.01% 483
2020
Q3 		$648K Buy
5,911
+162
+3% +$18K 0.01% 411
2020
Q2 		$608K Hold
5,749
– – 0.01% 421
2020
Q1 		$514K Buy
5,749
+27
+0.5% +$2.54K 0.01% 407
2019
Q4 		$571K Sell
5,722
-11
-0.2% -$1.04K 0.01% 446
2019
Q3 		$473K Hold
5,733
– – 0.01% 454
2019
Q2 		$473K Sell
5,733
-209
-4% -$16.4K 0.01% 454
2019
Q1 		$480K Sell
5,942
-682
-10% -$53.8K 0.01% 425
2018
Q4 		$503K Buy
6,624
+107
+2% +$8.36K 0.01% 399
2018
Q3 		$516K Buy
6,517
+90
+1% +$6.81K 0.01% 438
2018
Q2 		$451K Buy
6,427
+358
+6% +$25.8K 0.01% 465
2018
Q1 		$424K Buy
6,069
+357
+6% +$24.7K 0.01% 487
2017
Q4 		$396K Buy
5,712
+120
+2% +$8.09K ﹤0.01% 492
2017
Q3 		$379K Sell
5,592
-185
-3% -$11.7K ﹤0.01% 492
2017
Q2 		$394K Sell
5,777
-352
-6% -$23K 0.01% 473
2017
Q1 		$335K Hold
6,129
– – ﹤0.01% 478
2016
Q4 		$334K Sell
6,129
-94
-2% -$5.34K ﹤0.01% 478
2016
Q3 		$409K Sell
6,223
-16
-0.3% -$1.05K 0.01% 433
2016
Q2 		$377K Sell
6,239
-59
-0.9% -$3.43K 0.01% 436
2016
Q1 		$355K Sell
6,298
-979
-13% -$58.8K 0.01% 431
2015
Q4 		$494K Buy
7,277
+150
+2% +$9.83K 0.01% 364
2015
Q3 		$454K Hold
7,127
– – 0.01% 371
2015
Q2 		$454K Sell
7,127
-975
-12% -$66.8K 0.01% 399
2015
Q1 		$554K Sell
8,102
-125
-2% -$8.69K 0.01% 379
2014
Q4 		$579K Hold
8,227
– – 0.01% 349
2014
Q3 		$588K Hold
8,227
– – 0.01% 344
2014
Q2 		$611K Sell
8,227
-1,846
-18% -$133K 0.01% 351
2014
Q1 		$654K Sell
10,073
-200
-2% -$12.9K 0.01% 328
2013
Q4 		$610K Buy
10,273
+100
+1% +$5.43K 0.01% 337
2013
Q3 		$528K Buy
10,173
+1,500
+17% +$75.3K 0.01% 344
2013
Q2 		$410K Buy
+8,673
New +$442K 0.01% 347

Other funds holding AZN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
CAM
Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return
MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

Davenport & Co's AZN Position: Q2 2026 in Review

Davenport & Co increased its AstraZeneca (AZN) stake by 5.1% in Q2 2026, buying an estimated $301K and bringing the position to 32,897 shares worth $6.24M. The position accounts for 0.03% of the portfolio, ranked #328.

Davenport & Co first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 351 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Davenport & Co held 32,897 shares of AstraZeneca worth $6.24M as of Q2 2026.
  • Davenport & Co bought 1,600 AstraZeneca shares in Q2 2026, an estimated $301K.
  • AstraZeneca made up 0.03% of Davenport & Co's portfolio in Q2 2026, its #328 holding.
  • Davenport & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • 351 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.